Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocugen (OCGN) EBITDA (2016 - 2025)

Ocugen's EBITDA history spans 12 years, with the latest figure at -$17.7 million for Q4 2025.

  • For Q4 2025, EBITDA fell 27.77% year-over-year to -$17.7 million; the TTM value through Dec 2025 reached -$67.8 million, down 25.56%, while the annual FY2025 figure was -$67.8 million, 25.56% down from the prior year.
  • EBITDA reached -$17.7 million in Q4 2025 per OCGN's latest filing, up from -$20.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$7.1 million in Q1 2021 to a low of -$26.0 million in Q2 2021.
  • Average EBITDA over 5 years is -$16.5 million, with a median of -$15.3 million recorded in 2024.
  • Peak YoY movement for EBITDA: tumbled 618.1% in 2021, then skyrocketed 50.99% in 2023.
  • A 5-year view of EBITDA shows it stood at -$14.6 million in 2021, then plummeted by 53.61% to -$22.4 million in 2022, then surged by 50.99% to -$11.0 million in 2023, then decreased by 26.22% to -$13.9 million in 2024, then dropped by 27.77% to -$17.7 million in 2025.
  • Per Business Quant, the three most recent readings for OCGN's EBITDA are -$17.7 million (Q4 2025), -$20.0 million (Q3 2025), and -$14.8 million (Q2 2025).